FUNDED PROJECTS:
CANCER

cartell MaratóIn the 2004 Marató, which was dedicated to cancer, 260 projects were presented and these were assessed by 169 scientists specialising in these diseases, according to their quality, methodology and relevance. This assessment was managed by the Catalan Agency for Health Technology Assessment and Research, of the Catalan Ministry of Health.
In accordance with the proposal of the scientific Advisory Committee of the Fundació La Marató de TV3, the Board agreed to distribute € 7,692,513 to the following 31 research projects of excellence:

Identification and characterisation of the tumorigenesis mechanisms mediated by the HER2 carboxyterminal fragments

  • Dr. Joaquín V. Arribas López
    Hospital Universitari Vall d'Hebron
Fund: 248.750 €

Identification of a predictive gene expression profile of tumour response and survival in locally advanced head and neck carcinoma

  • Dr. Agustí Barnadas Molins
    Hospital de la Santa Creu i Sant Pau
Fund: 245.956 €

Lipoaspirate mesenchymal stem cells of: therapeutic vehicles that are located in tumours.

  • Dr. Jerónimo Blanco Fernández
    Centre d'Investigació Cardiovascular de Barcelona
Fund: 164.505 €

Effect of anomalous ZAP-70 expression on chronic lymphoproliferative syndromes.

  • Dr. Francesc Bosch Albareda
    Hospital Clínic i Provincial de Barcelona
Fund: 154.375 €

Genetic variability of the papilloma virus in cervical adenocarcinoma.

  • Dr. Francesc Xavier Bosch José
    Institut Català d'Oncologia
  • Dr. Chris J. L. M. Meijer
    VU University Amsterdam
  • Dr. Massimo Tommasino
    International Agency for Research on Cancer Lyon
Fund: 490.168 €

Chromatin epigenetic regulation proteins as targets in anticarcinogenic strategies.

  • Dr. Miquel Coll Capella
    Institut de Biologia Molecular de Barcelona
Fund: 245.700 €

Comparative prospective study of ganglion staging between the standard haematoxylin-eosin technique and immunohistochemistry with cytokeratins in stage I-II colorectal carcinoma: prognostic correlation.

  • Dra. Miriam Cuatrecasas Freixas
    Hospital Universitari Vall d'Hebron
Fund: 37.806 €

Analysis of the role of the fucosyl- and sialyl transferases in metastatic cell behaviour.

  • Dra. Carme de Bolós Pi
    Institut Municipal d'Investigació Mèdica
  • Dr. Pere Clapés Saborit
    Institut d'Investigacions Químiques i Ambientals de Barcelona
  • Dra. Rosa Peracaula Miró
    Facultat de Ciències Universitat de Girona
Fund: 361.188 €

Genes-environment interaction in the aetiology of lymphomas in a multicentre European study.

  • Dra. Silvia de Sanjosé Llongueras
    Institut Català d'Oncologia
Fund: 249.521 €

Cooperation of oncoproteins in the development of leukaemia

  • Dr. Luciano Di Croce
    Centre de Regulació Genòmica
Fund: 184.750 €

Identification of specific inhibitors of betacatenin transcriptional activity in tumour progression

  • Dra. Mireia Duñach Masjuan
    Facultat de Medicina. Universitat Autònoma de Barcelona
  • Dr. Josep Baulida Estadella
    Institut Municipal d'Investigació Mèdica
  • Dr. Antoni Riera Escalé
    Institut de Recerca Biomèdica de Barcelona
Fund: 319.000 €

Study of the nuclear functions of IKK associated with tumorigenesis

  • Dr. Lluís Espinosa Blay
    Institut de Recerca Oncològica
  • Dr. Marty W. Mayo
    School of Medicine Virginia
Fund: 250.000 €

Study of peripheral tolerance to the non-structural protein NS3 of the hepatitis C virus (HCV) to develop immunotherapy against HCV infection for the prevention of hepatocarcinoma

  • Dr. Joan Ignasi Esteban Mur
    Hospital Universitari Vall d'Hebron
Fund: 165.000 €

Overexpression of the WT1 gene for monitoring the minimal residual disease in acute myeloblastic leukaemia

  • Dr. David Gallardo Giralt
    Institut Català d'Oncologia
Fund: 73.280 €

Endoscopic ultrasound with fine needle aspiration puncture (EUS-FNA) in mediastinal restaging follow neo-adjuvant therapy of patients with non-small-cell lung cancer (NSCLC). Therapeutic impact and cost-effectiveness study.

  • Dra. M. Àngels Ginès Gibert
    Hospital Clínic i Provincial de Barcelona
Fund: 79.375 €

Colonisation and infection by Escherichia coli producing broad spectrum betalactamases in neutropenic patients with cancer

  • Dr. Francesc Gudiol Munté
    Hospital Universitari de Bellvitge
Fund: 187.500 €

A new strategy for immune regulation of tumour growth based on the CD69 molecule as target

  • Dra. Pilar Lauzurica Gómez
    Facultat de Biologia Universitat de Barcelona
Fund: 235.535 €

Do cancer cells imitate the strategy of embryonic stem cells to become immortal?

  • Dra. Matilde Esther Lleonart Pajarin
    Hospital Universitari Vall d'Hebron
  • Dr. Zhao-Qi Wang
    International Agency for Research on Cancer Lyon
  • Dr. David Hugh Beach
    Oncology Laboratory at the WIBR, UCL, London
Fund: 448.250 €

Genetic and environmental factors and in the aetiology and prognosis of cancer of the bladder

  • Dra. Núria Malats Riera
    Institut Municipal d'Investigació Mèdica
  • Dra. María Luz Calle Rosingana
    Escola Politècnica Superior de Vic
  • Dr. Javier Benítez Ortiz
    Centro Nacional de Investigaciones Oncológicas (CNIO)
Fund: 448.526 €

Molecular alterations in the development and progression of endometrial carcinoma

  • Dr. Xavier Matias-Guiu Guia
    Hospital Arnau de Vilanova
  • Dr. Miguel Abal Posada
    Hospital Universitari Vall d'Hebron
  • Dr. Jaime Prat Díaz de Losada
    Hospital de la Santa Creu i Sant Pau
  • Dr. José Palacios Calvo
    Centro Nacional de Investigaciones Oncológicas (CNIO)
Fund: 451.875 €

Involvement of the human hepatitis A virus receptor (hHAVcr-1) in the development and progression of renal carcinoma. Value as diagnostic and prognostic marker in bladder and kidney carcinomas

  • Dra. Anna Meseguer Navarro
    Hospital Universitari Vall d'Hebron
Fund: 204.625 €

Transduction control in pancreatic cancer: a new therapeutic strategy?

  • Dra. Pilar Navarro Medrano
    Institut Municipal d'Investigació Mèdica
Fund: 244.668 €

Functional characterisation of the PTOV1-flotillin-1 complex in modulating the proliferation of cancer cells: mitotic control and interaction with the Notch pathway

  • Dra. Rosanna Paciucci Barzanti
    Hospital Universitari Vall d'Hebron
Fund: 154.973 €

Role of 4F2hc in tumorigenesis

  • Dr. Manuel Palacín Prieto
    Institut de Recerca Biomèdica de Barcelona
  • Dra. Maria Antonia Lizarbe Iracheta
    Facultad de Ciencias Químicas. Universidad Complutense de Madrid
  • Dr. Joaquin Abian Moñux
    Institut d'Investigacions Biomèdiques de Barcelona
Fund: 388.875 €

Study and identification of new senescence genes and pivot or wildcard factors in cell signalling, angiogenesis and invasiveness in colon and breast carcinomas. A clinical-pathological correlation

  • Dr. Santiago Ramón y Cajal
    Hospital Universitari Vall d'Hebron
Fund: 245.453 €

Screening of proteoglycans for ADAMTS proteases and implications in angiogenesis and in metastatic processes

  • Dr. Juan Carlos Rodríguez-Manzaneque
    Hospital Universitari Vall d'Hebron
Fund: 248.733 €

Regulation of the transduction pathways of presenilin-dependent signals in skin cancer

  • Dr. Francesc Solé Ristol
    Hospital del Mar
Fund: 216.250 €

Genetic characterisation of the B lymphomas of the marginal zone: nodal, primary splenic and extranodal of mucosa associated lymphoid tissue (MALT).

  • Dr. Francesc Solé Ristol
    Hospital del Mar
Fund: 136.500 €

New molecules in the diagnosis and therapy of prostate and breast cancer. Modulation of tumour growth by the chemokine CX3CL1 (fractalkine).

  • Dr. Timothy Thomson Okatsu
    Institut de Biologia Molecular de Barcelona
  • Dr. Pedro Luis Fernández Ruiz
    Hospital Clínic i Provincial de Barcelona
  • Dr. Santos Mañes Brotón
    Centro Nacional de Biotecnología. Madrid
Fund: 480.000 €

Telomeric dysfunction associated with chromosome instability in human mammary epithelial cells

  • Dra. Laura Tusell Padrós
    Facultat de Ciències UAB
Fund: 96.375 €

Institute Identification of new therapeutic targets in refractory germinal tumours

  • Dr. Francesc Viñals Canals
    Facultat de Medicina CSUB
  • Dr. Francisco Javier García del Muro Solans
    Institut Català d'Oncologia
Fund: 235.000 €
Anar al contingut